

## 36-3740: Anti-CDw17 (Lactosylceramide or LacCer) Monoclonal Antibody(Clone: HO18.3G-6.F5)

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	HO18.3G-6.F5
<b>Application :</b>	FACS,IF
<b>Reactivity :</b>	Human
<b>Alternative Name :</b>	Lactosylceramide; LacCer; $\beta$ -D-galactosyl-(1-4)- $\beta$ -D-glucosyl-(1-1')-ceramide;CDw17
<b>Isotype :</b>	Mouse IgM, kappa
<b>Immunogen Information :</b>	$\beta$ -2 Microglobulin associated proteins from a detergent lysate of human PBL

### Description

CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor  $\gamma$ -induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.

### Product Info

<b>Amount :</b>	20 $\mu$ g / 100 $\mu$ g
<b>Content :</b>	200 $\mu$ g/ml of Ab Purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
<b>Storage condition :</b>	Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.

### Application Note

Flow Cytometry (1-2ug/million cells); Immunofluorescence (1-2ug/ml);